| | | 13–15 mg/kg/d | 18–22 mg/kg/d | value | | (n = 36) | (n = 37) |
| | Age, year | 52.0 (46.0, 58.8) | 52.0 (46.5 – 56.0) | 0.623 | | Female, no. (%) | 30 (83.3%) | 33 (89.2%) | 0.476 | | Fatigue (%) | 11/36 (30.6%) | 13/37 (35.1%) | 0.677 | | Pruritus (%) | 18 (50.0%) | 19 (51.4%) | 0.995 | | PLT, 109/L | 170.0 (102.3, 234.5) | 181.0 (137.5, 235.5) | 0.318 | | TB, μ mol/L | 17.4 (14.1, 27.3) | 15.3 (11.2, 22.4) | 0.072 | | ALP, IU/L | 281.0 (216.0, 394.5) | 238.0 (203.0, 338.0) | 0.156 | | AST, IU/L | 58.5 (45.0, 94.0) | 54.0 (42.5 – 67.0) | 0.180 | | ALT, IU/L | 64.0 (40.5, 77.0) | 53.0 (44.0, 78.0) | 0.938 | | ALB, g/L | 43.3 (39.7, 47.5) | 45.4 (43.2, 46.6) | 0.133 | | GLB, g/L | 36.7 (31.3, 39.2) | 34.3 (30.6, 35.6) | 0.090 | | GGT, IU/L | 220.0 (123.3, 288.0) | 161.0 (110.5 – 261.5) | 0.227 | | IGM, mg/L | 3145.0 (1787.0, 4265.0) | 3000.0 (2090.0, 3815.0) | 0.728 | | CHOL, mmol/L | 5.3 (4.4, 6.9) | 6.0 (5.3 – 6.4) | 0.348 | | APRI | 1.17 (0.64, 1.18) | 0.97 (0.61, 1.27) | 0.120 | | FIB-4 | 3.02 (1.49, 5.62) | 2.14 (1.41, 3.00) | 0.085 | | AMA, no. (%) | 22 (61.1%) | 29 (78.3%) | 0.108 | | MND (%) | 0 (0%) | 1 (2.7%) | >0.999 | | Anti-Sp100 | 0/5 (0%) | 1/7 (14.3%) | >0.999 | | RL/M (%) | 11 (30.6%) | 12 (32.4%) | 0.863 | | Anti-gp210 | 1/5 (20.0%) | 2/7 (28.6%) | >0.999 | | Liver cirrhosis, no. (%) | 12 (33.3%) | 7 (18.9%) | 0.181 |
|
|
Only 12 cases in our trial underwent investigations for anti-Sp100 and anti-gp210 by immunoblotting. Note. PLT, platelet count; TB, total bilirubin; ALP, alkaline phosphatase; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALB, albumin; GLB, globulin; GGT, γ-glutamyltransferase; IGM, immunoglobulin M; CHOL, cholesterol; PT, prothrombin time; APRI, aspartate aminotransferase/platelet ratio index; FIB-4, fibrosis index based on the four factors; AMA, antimitochondrial antibody; MND, multiple nuclear dots; RL/M, rim-like/membranous. |
